Lennox Gastaut Syndrome

Danish pharma Lundbeck vastly increased its offer to buy Longboard Pharmaceuticals over six months as other parties came to the dealmaking table, a new SEC filing shows. Lundbeck initially proposed $29 per share $LBPH on April 19 to buy the Phase 3 neurology biotech. By Oct. 14, when the $2.6 billion cash deal was announced, it had raised its offer to $60, according to an SEC filing on Wednesday morning. At the time, Lundbeck CEO Charl van Zyl told Endpoints News the deal was within the “benchmark premium” for companies with assets in Phase 3. “We believe we have fundamentally not overpaid for this asset,” he said in the interview. Longboard said last month that its 5-HT2C superagonist known as bexicaserin had entered Phase 3 for Dravet syndrome and has broader plans to test the treatment in other epileptic encephalopathies like Lennox-Gastaut syndrome. Lundbeck had been intrigued by the Phase 1b/2a data that Longboard shared on Jan. 2 for patients who experience seizures associated with developmental and epileptic encephalopathies. That data skyrocketed Longboard’s stock price from $6.03 on Dec. 29 to $25.10 on Jan. 2. Shortly after the data release, Lundbeck representatives met with Longboard CEO Kevin Lind at the annual JP Morgan Healthcare Conference. Lundbeck would go on to increasingly raise its offer from $29.00 to $34.50, then $54.00 and $59.00. Lind wanted $62.00 a share, but they eventually settled on $60.00. During the process, Longboard had also talked with other undisclosed companies, codenamed Parties A, B, C and D, according to another SEC filing on Wednesday. Party A had submitted a few offers, including one as high as $60.00 on Sept. 27. But on Oct. 2, Party A told Longboard it was no longer interested because of “various perceived risks,” according to the SEC document.

Insight 数据库「医药交易」模块显示，本周全球范围内共发生 13 项医药交易（截至 10 月 18 日），涉及辉瑞、诺华、赛诺菲、百裕制药、灵北制药、晖致医药等公司。 其中： 大额交易中，有灵北制药约 25 亿美元收购罕见病公司获得癫痫新药，辉瑞超 15 亿美元布局分子胶降解剂； 在中国创新药出海方面，百裕制药开发的一款小分子抗肿瘤药以 11.7 亿美元的价格授予诺华； 另外，还有赛诺菲、灵北制药、晖致医药等公司达成新合作，涉及放射性配体疗法、SGLT-1/2 双效抑制剂、5-HT2C 受体激动剂、YKL-40 抑制剂等创新产品。 下面，Insight 数据库将节选部分备受关注的交易案例做介绍，仅供读者参阅。 跨国药企竞相布局新疗法   辉瑞超 15 亿美元布局分子胶 TRIANA Biomedicines 与辉瑞达成合作，以发现包括肿瘤学在内多个疾病领域多个靶点的新型分子胶降解剂。为此，前者将获得 4900 万美元预付款，并有资格获得超过 15 亿美元的潜在未来里程碑以及分层特许权使用费。 根据协议，TRIANA 公司将利用其分子胶发现平台，领导发现和确定潜在的开发候选管线。而辉瑞将拥有独家许可选择权，以进一步推进临床前和临床开发。   诺华约 11.7 亿美元引进百裕制药小分子抗肿瘤药 诺华与百裕制药签订独家许可协议，获得百裕制药一款在研抗肿瘤小分子药物的全球独家开发及商业化权利。根据协议，百裕制药将收到 7000 万美元首付款，及可达 11 亿美元的开发、注册、商业化等里程碑付款和相应特许权使用费。 百裕制药专注银杏核心药效成分研究二十余年，聚焦肿瘤及自身免疫疾病领域。此次授权的产品正是该公司创新药团队发现的一款治疗恶性肿瘤小分子创新药。   赛诺菲 3 亿欧元股权投资 Orano Med 赛诺菲与 Orano Med 签署协议，加速下一代放射性配体药物的开发。根据协议，赛诺菲将向 Orano Med 进行 3 亿欧元的股权投资。基于 Orano Med 的专业知识及其放射性配体药物研发管线，双方将共同专注于基于铅-212 同位素的α粒子放射性配体疗法的发现、设计和临床开发。 上个月，赛诺菲已与 RadioMedix 和 Orano Med 达成总额约 3.2 亿欧元合作，以共同开发基于同位素铅的放射性配体疗法（RLT）用于癌症治疗。该合作则主要聚焦于后期临床项目 AlphaMedix，用于治疗进展性生长抑素受体表达神经内分泌肿瘤（NET）成年患者。 其它授权合作   灵北制药收购公司获得癫痫新药 灵北制药（Lundbeck）和 Longboard Pharmaceuticals 达成协议，灵北制药将收购 Longboard 公司并获得潜在「best-in-class」产品 bexicaserin（LP352）。该交易预计将于 2024 年第四季度完成，总交易价值约为 26 亿美元股权价值和 25 亿美元现金净额。 Bexicaserin 是一款高选择性、口服、新型 5-HT2C 受体激动剂，正在开发用于治疗与发育性癫痫性脑病（DEE）相关的癫痫发作，包括 Dravet 综合征、Lennox-Gastaut 综合征和其他罕见癫痫。目前，该产品用于治疗 Dravet 综合征相关癫痫发作的全球 3 期试验正在进行中。   晖致医药 2500 万美元引进 SGLT-1/2 双效抑制剂 晖致医药（Viatris）获得 Lexicon Pharmaceutical 独家许可，可在美国和欧洲以外的所有适应症中商业化 SGLT-1/2 双效抑制剂 Sotagliflozin，Lexicon 保留了该药在美国和欧洲所有适应症的独家商业化权利。为此，Lexicon 公司将获得 2500 万美元的预付款及潜在监管和商业里程碑付款。 Sotagliflozin 已于 2023 年 5 月获得美国 FDA 批准，用于降低成人患者的心血管死亡、因心力衰竭而住院或接受急救的风险。这些患者患有心力衰竭或 2 型糖尿病、慢性肾病，并携带其它心血管疾病风险因子。   Molecure 与 Ocean Biomedical 达成合作 Molecure 公司与 Ocean Biomedical 签署了一项独家许可协议，后者获得了在全球范围内进一步研究、开发、制造和商业化 Molecure 公司 OAT-3912 和其他选择性 YKL-40 抑制剂的独家权利。根据协议，Molecure 公司将获得 60 万美元的现金和股票作为初始补偿，并有望获得潜在里程碑付款，协议最高价值约为 3200 万美元。 该协议涵盖了「first-in-class」的小分子 YKL-40 抑制剂，包括先导分子 OAT-3912，它在各种癌症及炎症和纤维化疾病的临床前模型中显示出潜在治疗益处。   Orasis 公司 1800 万美元授出滴眼液韩国权益 Orasis Pharmaceuticals 授予 Optus pharmaceutical 在韩国商业化、进口和销售 0.4% Qlosi（盐酸匹罗卡品滴眼液）的权利，这是一种治疗成人老视的新型矫正滴眼液。 根据协议，这项合作其他条款包括预付款和关键里程碑的付款，共计 1800 万美元，此外还有韩国市场销售额的两位数特许权使用费。Optus 公司计划率先在韩国市场推出一种新的老视治疗药物，并计划在获得监管批准和销售批准后，于 2026 年在韩国推出 Qlosi。 除了上述案例，本周还有一些其它公司也达成了不同类型的合作，限于篇幅，此处不再一一介绍。欲了解本周更多授权合作信息，可点击阅读原文前往 Insight 数据库「医药交易」模块查看。 封面来源：站酷海洛 Plus 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。 编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验 点击阅读原文，立刻解锁！

SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Tickets are now available for the December 5, 2024 showing of It's All Your Fault, Tyler Price!, a new musical created by Emmy-Winning Composer Ben Decter (Lucifer) and Tony-Nominated Director Kristin Hanggi (Rock of Ages), which highlights the hardships and stigma of living with epilepsy and Lennox-Gastaut Syndrome (LGS). Epilepsy affects 50 million people worldwide and is the fourth most common neurological disease after migraines, stroke, and Alzheimer's Disease. Despite its prevalence and the fact that 1 in 26 Americans will develop epilepsy in their lifetime, awareness and research funding lag behind. In some cases, epilepsy can be controlled with currently available therapies, but this is not the case for Lennox-Gastaut Syndrome (LGS), a rare, severe, life-threatening epilepsy syndrome that develops in children and leads to lifelong disability. Approximately 1 million children and adults worldwide have LGS, yet no broadly effective treatments exist. The LGS Foundation has partnered with Decter and Hanggi to raise awareness and shine a light on what it is like to live with these disorders. "When my family was in crisis—my little girl, diagnosed with Lennox-Gastaut Syndrome, was having 100 seizures a day and we felt so isolated—I never imagined a musical would grow out of it. Writing these songs helped my family have difficult conversations and come together," says Decter in a statement. "It's All Your Fault, Tyler Price! is a fun, irreverent look at a family going through a really hard time—that everyone can relate to." "This musical is a true passion project for us. It's about dealing with struggles in our families and how challenging it is to be seen by those closest to us," adds Hanggi. "Through art, our characters learn to explore uncomfortable feelings—things that can be difficult to share or admit. We can't wait for Los Angeles—where I've gotten the opportunity to launch other new musicals—to see our show!" "Raising awareness of epilepsy and LGS has never been more critical," shares Dr. Tracy Dixon-Salazar, Executive Director of the LGS Foundation and mother to an adult daughter who has LGS. "For far too long have these conditions been kept in the shadows and not talked about. We are thrilled to partner on this project and help educate the community in a fun and approachable way. We hope folks will come out and enjoy the show and learn about epilepsy and LGS in the process." About the LGS Foundation The LGS Foundation is a nonprofit organization dedicated to improving the lives of individuals impacted by LGS through advancing research, awareness, education, and family support. To learn more, visit . SOURCE Lennox-Gastaut Syndrome (LGS) Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED